SheMed raises €43m to scale UK operations

London-based women’s health platform SheMed has raised €43m to expand its UK operations and further develop its personalised healthcare platform.

The company, founded by sisters Olivia and Chloe Ferro in April 2024, will use the investment to scale its medical and technology teams, strengthen clinical infrastructure and enhance its data-driven systems.

SheMed offers weight management programmes using GLP-1 drugs — treatments that mimic a natural hormone regulating blood sugar and appetite — alongside wellness tracking and 24/7 support through its digital platform.

 Olivia Ferro, co-founder and chief executive of SheMed, said: “For more than a decade, I searched for answers to an undiagnosed health issu.

“As a GLP-1 patient myself, I know how transformative the right diagnosis and treatment can be.

“We built SheMed to give women the personalised support I struggled to find: care that listens, understands and empowers.”

The funding comes amid a broader wave of investment in UK and European health technology, particularly in preventative care and women’s health.

Other UK-based companies in similar areas have also raised significant sums this year, including Numan, which secured €51.6m to expand its digital healthcare platform into female health, and Hormona, which raised €7.8m for its AI-driven hormone health tracking solution.

Related UK ventures such as Perci Health and CoMind have also attracted new funding for personalised, data-led healthcare models.

According to analysis by EU-Startups, UK start-ups have raised about €14.7bn so far in 2025, signalling strong investor confidence in the country’s innovation sector.

The new investment will also fund SheMed’s research and patient-experience initiatives, aimed at improving access to personalised care for women across the UK.

Later this month, SheMed plans to publish results from what it describes as the first female-focused GLP-1 clinical study.

The findings are expected to reveal how GLP-1 medications affect women’s hormonal and metabolic responses, helping to refine future treatment approaches.